Identification

Name
Azelnidipine
Accession Number
DB09230
Type
Small Molecule
Groups
Approved, Investigational
Description

Azelnidipine is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with minimal increase in heart rate [3]. It is currently being studied for post-ischemic stroke management [4].

Structure
Thumb
Synonyms
Not Available
External IDs
CS-905
International/Other Brands
Azelnidipine Chemipha / Azelnidipine FFP / Azelnidipine JG / Azelnidipine KOG / Azelnidipine Nichi-Iko / Azelnidipine Tanabe / Azelnidipine TCK / Azelnidipine Teva / Azelnidipine Towa / Azelnidipine YD / Beiqi / Calblock / Rezaldas HD / Rezaltas LD
Categories
UNII
PV23P19YUG
CAS number
123524-52-7
Weight
Average: 582.657
Monoisotopic: 582.247834831
Chemical Formula
C33H34N4O6
InChI Key
ZKFQEACEUNWPMT-UHFFFAOYSA-N
InChI
InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
IUPAC Name
3-[1-(diphenylmethyl)azetidin-3-yl] 5-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CC(C)OC(=O)C1=C(C)NC(N)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics

Azelnidipine is a vasodilator that induces a gradual decrease in blood pressure in hypertensive patients. Unlike other members of its drug class, azelnidipine does not induce reflex tachycardia due to vasodilation. This is likely due to the fact that it elicits a gradual fall in blood pressure

It also exhibits a prolonged hypotensive effect and has been shown to have a strong anti-arteriosclerotic action in vessels due to its high affinity for vascular tissue and antioxidative activity [2].

Clinical studies have demonstrated that azelnidipine markedly reduced heart rate and proteinuria in hypertensive patients by inhibiting sympathetic nerve activity. Azelnidipine has also been confirmed to have cardio-protective, neuroprotective, and anti-atherosclerotic properties, and has also been found to prevent insulin resistance [2].

Mechanism of action

Azelnidipine inhibits trans-membrane Ca2+ influx through the voltage-dependent channels of smooth muscles in vascular walls. Ca2+ channels are classified into various categories, including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ channels. The L-type Ca2+ channels [6]. Normally, calcium induces smooth muscle contraction, contributing to hypertension. When calcium channels are blocked, the vascular smooth muscle does not contract, resulting in relaxation of vascular smooth muscle walls and decreased blood pressure.

TargetActionsOrganism
UVoltage-dependent L-type calcium channel subunit beta-1
agonist
Human
Absorption

Oral ingestion of azelnidipine demonstrates rapid and dose-dependent absorption [6].

Volume of distribution

In a Chinese study examining the pharmacokinetics of the drug, the volume of distribution was found to be 1749 +/- 964 [7].

Protein binding

Azelnidipine is widely bound to human plasma proteins (90%–91%) [L3183].

Metabolism

Like most members of its class, azelnidipine primarily undergoes first-pass hepatic metabolism. Azelnidipine is metabolized by hepatic cytochrome P450 (CYP) 3A4 and has no active metabolite product. It may interact with other drugs or compounds that are substrates for this enzyme.

Azelnidipine is lipophilic and has a potent affinity for membranes of vascular smooth muscle cells [6].

Route of elimination

In one study, following a single 4mg oral dose of 14C-labeled azelnidipine in humans, about 26% of the drug was thought to br excreted in the urine and 63% in the feces during the 1 week period post administration [2].

Half life

16 –28 hours [7].

Clearance
Not Available
Toxicity

As with any calcium channel blocker toxicity, bradycardia and hypotension may result from overdose. The treatment of patients with bradycardia and hypotension begins with supportive therapy and atropine, however, patients with severe toxicity do not have an adequate response and must be managed more aggressively.

Calcium plays an imperative role in myocardial contractility, automaticity and vascular tone. Administration of exogenous calcium is of benefit in cases of toxicity [8].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Azelnidipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Azelnidipine.Vet Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Azelnidipine.Approved, Investigational
AmobarbitalThe metabolism of Azelnidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Azelnidipine.Approved, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Azelnidipine.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Azelnidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Azelnidipine.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Azelnidipine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Azelnidipine.Experimental
BarbexacloneThe metabolism of Azelnidipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Azelnidipine can be increased when combined with Barbital.Illicit
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Azelnidipine.Approved, Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Azelnidipine.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Azelnidipine.Experimental
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Azelnidipine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Azelnidipine.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Azelnidipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Azelnidipine.Approved
Calcium AcetateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Azelnidipine.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Azelnidipine.Experimental
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Azelnidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Azelnidipine.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Azelnidipine.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Azelnidipine.Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Azelnidipine.Approved, Investigational
CimetidineThe serum concentration of Azelnidipine can be increased when it is combined with Cimetidine.Approved, Investigational
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azelnidipine.Approved
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Azelnidipine.Approved, Vet Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Azelnidipine.Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Azelnidipine.Approved, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Azelnidipine.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Azelnidipine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Azelnidipine.Approved
EfavirenzThe serum concentration of Azelnidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Azelnidipine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Azelnidipine.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Azelnidipine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Azelnidipine.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Azelnidipine.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Azelnidipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Azelnidipine.Approved, Investigational, Vet Approved
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Azelnidipine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Azelnidipine.Approved, Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Azelnidipine.Approved, Investigational
HexobarbitalThe metabolism of Azelnidipine can be increased when combined with Hexobarbital.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Azelnidipine.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Azelnidipine.Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Azelnidipine.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Azelnidipine.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Azelnidipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Azelnidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Azelnidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Azelnidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Azelnidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Azelnidipine.Experimental
MethohexitalThe metabolism of Azelnidipine can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Azelnidipine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Azelnidipine.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Azelnidipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Azelnidipine.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Azelnidipine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Azelnidipine.Vet Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Azelnidipine.Experimental
NafcillinThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Azelnidipine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Azelnidipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Azelnidipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Azelnidipine.Investigational
NitroprussideAzelnidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Azelnidipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Azelnidipine.Approved, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Azelnidipine.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Azelnidipine.Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Azelnidipine.Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Azelnidipine.Approved, Investigational
PentobarbitalThe metabolism of Azelnidipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Azelnidipine can be increased when combined with Phenobarbital.Approved, Investigational
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Azelnidipine.Approved, Investigational, Vet Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Azelnidipine.Approved
PrimidoneThe metabolism of Azelnidipine can be increased when combined with Primidone.Approved, Vet Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Azelnidipine.Experimental
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Azelnidipine.Experimental
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Azelnidipine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Azelnidipine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Azelnidipine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Azelnidipine.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Azelnidipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Azelnidipine.Approved, Investigational, Vet Approved
SecobarbitalThe metabolism of Azelnidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Azelnidipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Azelnidipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Azelnidipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Azelnidipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Azelnidipine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Azelnidipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Azelnidipine.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Azelnidipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Azelnidipine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Azelnidipine.Approved
ThiamylalThe metabolism of Azelnidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Azelnidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Azelnidipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Azelnidipine.Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Azelnidipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Azelnidipine.Approved, Investigational, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Azelnidipine.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Azelnidipine.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Azelnidipine.Investigational
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Azelnidipine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245158/

General References
  1. Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T: Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol. 1989 Sep;51(1):57-64. [PubMed:2810942]
  2. Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S: Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007;57(11):698-704. doi: 10.1055/s-0031-1296670. [PubMed:18193691]
  3. DRUG: Azelnidipine [Link]
  4. Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study [Link]
  5. Azelnidipine MSDS [Link]
  6. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients [Link]
  7. Determination of azelnidipine by LC–ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers [Link]
  8. Calcium Channel Blocker Poisoning [Link]
External Links
KEGG Drug
D01145
PubChem Compound
65948
PubChem Substance
310265134
ChemSpider
59352
ChEBI
31247
ChEMBL
CHEMBL1275868
Wikipedia
Azelnidipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
4CompletedPreventionCoronary Artery Atherosclerosis / High Blood Pressure (Hypertension)1
4RecruitingTreatmentCerebral Small Vessels Disease1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)193-195[L1381]
water solubilityInsoluble in waterNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00082 mg/mLALOGPS
logP5.12ALOGPS
logP5.57ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)19.88ChemAxon
pKa (Strongest Basic)6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area137.03 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity172.06 m3·mol-1ChemAxon
Polarizability60.76 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0159-0900060000-c80c65ee0493cbc50569

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Trialkylamines / Amino acids and derivatives / Azetidines
show 11 more
Substituents
Diphenylmethane / Nitrobenzene / Dihydropyridinecarboxylic acid derivative / Nitroaromatic compound / Dihydropyridine / Aralkylamine / Dicarboxylic acid or derivatives / Hydropyridine / Vinylogous amide / Alpha,beta-unsaturated carboxylic ester
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB1
Uniprot ID
Q02641
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
65712.995 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. DRUG: Azelnidipine [Link]

Drug created on October 23, 2015 10:13 / Updated on March 02, 2018 03:47